Quick Facts

• Primary Therapeutic Domain: Management of breakthrough pain in patients with cancer.
• Patient Population: Indicated for adult patients (18 years and older).
• Required Baseline: Must already be tolerant to and receiving around-the-clock opioid therapy for their underlying persistent cancer pain.

Fentora is an approved treatment option used for the targeted management of breakthrough pain episodes in patients with cancer. Breakthrough pain refers to a transient flare of pain that occurs despite a patient receiving an opioid regimen for persistent pain.

This medication is specifically indicated for use in adult patients who meet criteria for opioid tolerance, meaning they are already accustomed to a steady, daily intake of other opioid medicines. The primary goal of therapy is to help address the acute, short-term pain flares that occur outside the coverage of their continuous pain management. Healthcare providers employ this agent as a tool to manage these episodes and support overall patient comfort.

It is important to note that this product is not intended for the management of acute or postoperative pain, nor is it for use in patients who are not opioid-tolerant.

Official Population Eligibility for Fentora

Fentora is approved for a highly specific patient population based strictly on regulatory requirements. It is indicated only for adult cancer patients (18 years and older) who are already opioid-tolerant, meaning they receive and are tolerant to continuous, around-the-clock opioid therapy for their persistent pain.

Absolute Contraindications

Regulatory documents explicitly forbid Fentora use in the following populations:

• Opioid non-tolerant patients: This is an absolute contraindication due to the risk of fatal respiratory depression.
• Type of Pain: It is contraindicated for the management of any non-cancer pain, including acute or postoperative pain, headache, or dental pain.
• Pre-existing Conditions: Patients with significant respiratory depression, acute or severe bronchial asthma, or known gastrointestinal obstruction (e.g., paralytic ileus) must not use this medicine.

Conditional and Restricted Use

• Pediatrics: Safety and efficacy are not established for children under 18 years of age.
• Geriatrics: Older adults (over 65) require increased caution during dose adjustments.
• Organ Function: Use with caution is mandated for patients with moderate or severe hepatic (liver) or renal (kidney) impairment.
• Pregnancy/Lactation: Use is not recommended during pregnancy due to the risk of fetal harm and Neonatal Opioid Withdrawal Syndrome. Use during lactation is also not recommended.

Interactions with other medicines and products

Fentora (Fentanyl Citrate) has a well-defined interaction profile based on its metabolic pathway and pharmacodynamic effects, as outlined in official government regulatory documents.

Pharmacokinetic Interaction (Metabolic)

The primary concern involves the Cytochrome P450 3A4 (CYP3A4) enzyme:

• CYP3A4 Inhibitors (both strong and moderate): Co-administration with agents like ketoconazole or ritonavir is officially warned to increase fentanyl plasma concentrations and the potential for prolonged opioid effects.
• CYP3A4 Inducers: Regulatory warnings specify that the discontinuation of an inducer (e.g., rifampin) can lead to a sudden increase in fentanyl plasma concentration and overdose risk.

Pharmacodynamic and Prohibited Combinations

Contraindicated/Not Recommended Combinations

Interacting Substance/Class	Official Interaction Restriction
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated; Fentora must not be used within 14 days of stopping MAOI treatment.
Mixed/Partial Opioid Agonists (e.g., buprenorphine)	Officially advised to avoid; may reduce analgesic effect or precipitate withdrawal.
CNS Depressants & Alcohol	Additive pharmacologic effect resulting in increased risk of respiratory depression and profound sedation.
Serotonergic Drugs	Concomitant use increases the risk of Serotonin Syndrome.

Population-Specific Note

Official labeling advises that patients with moderate or severe hepatic or renal impairment should be carefully monitored due to potential alterations in fentanyl clearance, which may intensify interaction risks.

The active substance in Fentora is fentanyl, which is highly lipophilic and rapidly crosses the blood-brain barrier to target the central nervous system. Fentanyl functions as a pure agonist at the mu-opioid receptor (mu-OR), a member of the G-protein coupled receptor (GPCR) superfamily, which is abundantly expressed on neuronal cell membranes in the brain and spinal cord.

Upon binding to the mu-OR, fentanyl induces a conformational change that facilitates the coupling and activation of inhibitory Gi/o-proteins. The activated Gi/o-protein complex subsequently dissociates, causing two primary intracellular effects: the inhibition of adenylyl cyclase, which results in decreased intracellular concentration of cyclic adenosine monophosphate (cAMP); and the activation of inwardly rectifying potassium channels ( K^+ channels) while inhibiting voltage-gated calcium channels ( Ca^2+ channels). The increased K^+ efflux and reduced Ca^2+ influx lead to neuronal hyperpolarization and a decrease in presynaptic neurotransmitter release. This modulation of neuronal excitability occurs in pathways that regulate ascending nociceptive signaling, as well as centers in the brainstem controlling respiratory drive and vagal tone. Specifically, activation of mu-ORs in the brainstem's respiratory centers reduces the responsiveness to carbon dioxide, inducing central respiratory depression, and activation in the medulla increases vagal tone, causing bradycardia.

The administration of Fentora is defined by its specialized design for transmucosal absorption and its role as an as-needed therapy for acute pain flares. The drug is strictly limited to adult patients who are already opioid tolerant, meaning they are accustomed to stable, around-the-clock opioid medication for their persistent cancer pain.

Fentora is available as an effervescent buccal tablet in multiple strengths, ranging from 100 µg to 800 µg of fentanyl base. The administration route requires the tablet to be placed whole either in the buccal cavity (between the cheek and gum) or sublingually (under the tongue). To ensure proper absorption, the tablet must not be split, chewed, crushed, or swallowed whole. Patients are instructed to avoid consuming food or drinks while the tablet is dissolving.

Usage begins with a dose titration process, typically starting at 100 µg. The goal is to establish a single, effective dose strength that provides adequate pain relief. Once the maintenance dose is determined, it is used on an intermittent basis. A maximum of two doses may be administered for a single breakthrough pain episode: the initial dose and one supplemental dose of the same strength if the first dose is insufficient after 30 minutes. To prevent excessive consumption, a minimum of 4 hours must elapse before treating a subsequent, separate pain episode. This regimen structure underscores the drug's intended use as a dedicated tool for intermittent, breakthrough pain management.

Research Evidence / Overview of Studies

Summary of Clinical Findings

Studies have explored the relationship between this fentanyl buccal tablet and the management of breakthrough pain episodes in certain adult patients. Research focuses on the drug's ability to deliver fentanyl through the buccal mucosa (cheek lining) and the resulting changes in pain intensity.

---

Key Efficacy Studies

Pain Resolution

Clinical trials examined patient-reported pain intensity scores following the administration of the fentanyl buccal tablet compared to placebo. These studies investigated the time to achieve pain relief and the proportion of patients reporting significant pain reduction. One key study examined the reported pain intensity difference scores (PID) at 30 minutes post-dose.

Comparative Administration

Studies also evaluated the drug's formulation and its influence on fentanyl absorption into the bloodstream compared to other transmucosal fentanyl products. Research assessed the time required to reach maximum concentration of fentanyl in the plasma to understand the drug's pharmacokinetics.

---

Safety and Patient Groups

Tolerability Profile

Studies evaluated the safety profile in adult patients with cancer who were already receiving and tolerant to around-the-clock opioid therapy. The reported incidence of specific adverse events, such as nausea, dizziness, and headache, was reviewed across trials. The tolerability profile was evaluated by the rate of discontinuation due to adverse events.

Suitability

Research has explored the use of the drug only in patients who have been diagnosed with chronic cancer pain and who are already taking and tolerant to other around-the-clock opioid medications. Individuals not meeting these criteria were generally excluded from the trials. It is not yet clear whether the observed effects vary significantly in non-cancer related pain.

Key Studies & References

1. EXECUTIVE SUMMARY - Fentanyl (Fentora) - NCBI Bookshelf (Review of clinical studies 14 and 3039)
2. Australian Public Assessment Report for Fentanyl citrate (Fentora) - TGA

Common questions about Fentora (FAQ)

---

Q: How quickly can someone expect Fentora to start working?

Studies and official information indicate that Fentora is formulated for a rapid onset of action. Clinical trials have reported a statistically significant improvement in pain intensity difference (PID) starting as early as 10 to 15 minutes after the tablet is administered, when compared to a placebo.

---

Q: How long does the effect of one Fentora dose typically last?

Clinical studies and official product information suggest that the pain-relieving effects of a single dose of this type of fentanyl product generally last about 2 to 3 hours. Because of this, dosing guidelines specify a minimum of 4 hours must elapse before treating a subsequent, separate breakthrough pain episode.

---

Q: What is the difference between Fentora and Actiq (fentanyl lozenges)?

According to official regulatory documents, Fentora (a buccal tablet) and Actiq (an oral transmucosal lozenge) are not bioequivalent, meaning they work differently in the body. They cannot be substituted microgram-for-microgram for each other due to significant differences in the way fentanyl is absorbed, which carries a risk of overdose.

---

Q: Can Fentora interact with grapefruit juice?

Official product information describes co-administration with strong CYP3A4 inhibitors as restricted. These substances interfere with the primary enzyme (CYP3A4) the body uses to process fentanyl. Grapefruit juice is known to inhibit this enzyme, which may increase fentanyl levels, posing a higher risk of respiratory problems.

---

Q: Does taking Fentora with or without food change how it works?

Administration instructions from regulatory sources recommend avoiding consuming food or drinks while the buccal tablet is dissolving in the mouth. This is noted as necessary to facilitate proper absorption across the cheek lining, which is essential for the drug to work as intended.

---

Q: Is Fentora the same as fentanyl patches?

Regulatory documents explicitly state that Fentora (a buccal tablet for breakthrough pain) is not interchangeable with fentanyl patches (transdermal products for around-the-clock pain). Regulatory documents caution against substituting one for the other, as the products have fundamentally different uses, dosing, and absorption profiles.

---

Q: What happens if someone chews the tablet instead of letting it dissolve?

Official administration instructions specify the tablet must not be split, chewed, crushed, or swallowed whole. Regulatory-linked information indicates that chewing the tablet can decrease the transmucosal absorption of the medicine. This may reduce the expected effectiveness against the acute pain episode.

---

Q: Why does Fentora have a specific Risk Evaluation and Mitigation Strategy (REMS)?

Fentora is included in the FDA's Transmucosal Immediate Release Fentanyl (TIRF) REMS Program. This strategy is required by the FDA to help mitigate the serious risks associated with this class of medicine, including misuse, abuse, addiction, overdose, and errors in prescribing or use.

---

Q: Is Fentora a new drug or has it been used for a long time?

Official policy and regulatory histories show that Fentora has been commercially available for over a decade. The FDA originally approved the drug, and new strengths were added and official programs updated in the late 2000s, reflecting its established use in the clinical setting.

---

Q: What is the required training or certification for healthcare providers prescribing Fentora?

Prescribers of Fentora must meet the requirements of the TIRF REMS Access program. The program requires prescribers to be knowledgeable about Schedule II opioids and the specific risks associated with this drug class. Additionally, many are subject to a one-time 8-hour training requirement on safe controlled substance prescribing.

---

Q: Does Fentora contain lactose or any common allergens?

Regulatory product information is required to list non-active ingredients that have known effects. While the full list of excipients (non-active ingredients) is not detailed here, official documents confirm the tablets contain a specific amount of sodium that varies by tablet strength.

---

Q: Why is it necessary to discontinue other short-acting opioids when starting Fentora?

Official regulatory instructions specify that patients should dispose of any other fentanyl product prescribed for breakthrough pain when starting Fentora. This is intended to prevent confusion and mitigate the risk of unintentionally taking multiple products.

How to Store and Dispose of FENTORA (Fentanyl Buccal Tablet)

FENTORA must be stored and disposed of according to strict regulatory requirements to ensure product stability and prevent fatal accidental ingestion or diversion of this Schedule II controlled substance.

Official Storage and Handling

Requirement	Description
Temperature	Store at controlled room temperature, specifically between 59 F and 86 F (15 C to 30 C). Do not freeze.
Packaging	Keep in the original blister unit and protected from moisture; tablets must not be stored once removed from the blister.
Child Safety	Must be stored in a secure location, out of the sight and reach of children, as accidental ingestion of one dose can be fatal.

Disposal Instructions

Unused or expired FENTORA must be disposed of promptly. The preferred method is through a drug take-back program. If a program is unavailable, official guidelines recommend flushing the tablets down the toilet to immediately remove the risk of accidental poisoning. The empty packaging should not be flushed.